The aim of this paper is to highlight the role for decision analysis in assessing outcomes of medical interventions at a population level. The basic steps of decision analysis are introduced and an illustrative hypothetical preventive intervention is examined. Specific modelling challenges that arise when estimating the population impact of an intervention are described and each is accompanied by an example. Decision analysis can provide useful information for health policy decision makers by identifying the intervention(s) with the largest beneficial impact on health over a wide range of assumptions. In addition, by focusing attention on the parameters with the greatest influence on projected outcomes, decision analysis can aid in identifying critical areas for future research.
Get full access to this article
View all access options for this article.
References
1.
Torrance GW.Utility approach to measuring health-related quality of life . Journal of Chronic Disease1987; 40: 593-603 .
2.
Gold M , Siegel J , Russell L , Weinstein M.Cost-effectiveness in Health and Medicine. New York: Oxford University Press , 1996.
3.
Doubilet PD , Begg CB , Weinstein MC , Braun P , McNeil BJ.Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach . Medical Decision Making1985; 5: 157-177 .
4.
Pass TM , Goldstein LP.A computerized aid for medical cost effectiveness analysis [Abstract] . Medical Decision Making1981; 1: 465-465 .
5.
Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) . Lancet1994; 344: 1383-1389 .
6.
Shepherd J , Cobbe SM , Ford I , Isles CG , Lorimer AR , Macfarlane PWet al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia . New England Journal of Medicine1995; 333: 1301-1307 .
7.
Downs JR , Clearfield M , Weis S , Whitney E , Shapiro DR , Beere PAet al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels . Journal of the American Medical Association1998; 279: 1615-1622 .
8.
The West of Scotland Coronary Prevention Study Group . A coronary primary prevention study of Scottish men aged 45-74 years: trial design . Journal of Clinical Epidemiology1992; 45: 849-860 .
9.
Shepherd J.A tale of two trials: The West of Scotland Coronary Prevention Study and the Texas Coronary Atherosclerosis Prevention Study . Atherosclerosis1998; 139: 223-229 .
10.
Downs JR , Beere PA , Whitney E , Clearfield M , Weiss S , Rochen Jet al.Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS) . American Journal of Cardiology1997; 80: 287-293 .
11.
Shepherd J.Preventing coronary artery disease in the west of Scotland: implications for primary prevention . American Journal of Cardiology1998; 82: 57T-59T .
12.
Johannesson M , Jönsson B , Kjekshus J , Olsson AG , Pedersen TR , Wedel H.Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease . New England Journal of Medicine1997; 336: 332-336 .
13.
Sonnenberg FA , Beck JR.Markov models in medical decision making: a practical guide . Medical Decision Making1993; 13: 322-338 .
14.
Fisher B , Costantino JP , Wickerham DL , Redmond CK , Kavanah M , Cronin WM.Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [see comments] . Journal of the National Cancer Institute1998; 90: 1371-1388 .
15.
Black WC , Nease RF, Jr , Welch HG.Determining transition probabilities from mortality rates and autopsy findings . Medical Decision Making1997; 17: 87-93 .
16.
Ries LAG , Kosary CL , Hankey BF , Miller BA , Harras A , Edwards BK eds. SEER Cancer Statistics Review, 1973-1994, National Cancer Institute. Bethesda, MD : NIH Pub. No. 97-2789, 1997.
17.
Tosteson AN , Rosenthal DI , Melton LJ III , Weinstein MC.Cost-effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy . Annals of Internal Medicine1990; 113: 594-603 .
18.
Col N , Pauker S , Goldberg R , Eckman M , Orr R , Ross E , Wong J.Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women . Archives of Internal Medicine1999; 159: 1458-1466 .
19.
Marshall D , Johnell O , Wedel H.Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures . British Medical Journal1996; 312: 1254-1259 .
20.
Riggs BL , Hodgson SF , O'Fallon WM , Chao EYS , Wahner HW , Muhs JMet al.Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis . New England Journal of Medicine1990; 322: 802-809 .
21.
Bucher HC , Guyatt GH , Cook DJ , Holbrook A , McAlister FA for the Evidence-Based Medicine Working Group . Users guides to the medical literature: XIX. Applying clinical trial results A. How to use an article measuring the effect of an intervention on surrogate end points . Journal of the American Medical Association1999; 282: 771-778 .
22.
Pocock SJ , Abdalla M.The hope and hazards of using compliance data in randomized controlled trials . Statistics in Medicine1998; 17: 303-317 .
23.
The West of Scotland Coronary Prevention Study Group . Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study . European Heart Journal1997; 18: 1718-1724 .
24.
Andrade SE , Walker AM , Gottlieb LKet al.Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings?New England Journal of Medicine1995; 332: 1125-1131 .
25.
Albert JM , Demets BL.On a model-based approach to estimating efficacy in clinical-trials . Statistics in Medicine1994; 13: 2323-2335 .
26.
Atkinson EN.A Bayesian strategy for evaluating treatments applicable only to a subset of patients . Statistics in Medicine1997; 16: 1803-1815 .
27.
Tosteson ANA , Weinstein MC , Hunink MGM , Mittleman MA , Williams LW , Goldman PAet al.Cost-effectiveness of populationwide educational approached to reduce serum cholesterol levels . Circulation1997; 95: 24-30 .
28.
Pharoah PDP , Sanderson SP.Health promotion in primary care: modeling the impact of intervention on coronary hearth disease and stroke . Journal of Public Health Medicine1995; 17: 150-156 .
29.
Fisher ES , Welch HG.Avoiding the unintended consequences of growth in medical care . Journal of the American Medical Association1999; 281: 446-453 .
30.
Hersh AL , von Reyn CF , Tosteson ANA.Evaluation of skin testing for tuberculosis in health care workers: cost analysis of dual skin testing versus current guidelines [Abstract] . Medical Decision Making1997; 17: 526-526 .
31.
Weinstein MC , Coxson PG , Williams LWet al.Forecasting coronary heart disease incidence, mortality and cost - the coronary heart disease policy model . American Journal of Public Health1987; 77: 1417-1426 .
32.
Goldman L , Weinstein MC , Williams LW.Relative impact of targeted versus population-wide cholesterol interventions on the incidence of coronary heart disease - projections of the coronary heart-disease policy model . Circulation1989; 80: 254-260 .
33.
Tosteson ANA , Weinstein MC , Williams LW , Goldman L.Long-term impact of smoking cessation on the incidence of coronary heart-disease . American Journal of Public Health1990; 80: 1481-1486 .
34.
Tsevat J , Weinstein MC , Williams LW , Tosteson AN , Goldman L.Expected gains in life expectancy from various coronary heart-disease risk factor modifications . Circulation1991; 83: 1194-1201 .
35.
Hunink MGM , Goldman L , Tosteson ANAet al.The recent decline in mortality from coronary heart disease, 1980-1990 - the effect of secular trends in risk factors and treatment . Journal of the American Medical Association1997; 277: 535-542 .
36.
Brown AD , Garber AM.Cost effectiveness of coronary heart disease prevention strategies in adults . Pharmacoeconomics1998; 14: 27-48 .
37.
Garber AM , Solomon NA.Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease . Annals of Internal Medicine1999; 130: 719-728 .
38.
Eddy DM.Screening for breast cancer . Annals of Internal Medicine1989; 111: 389-399 .
39.
Lindfors KK , Rosenquist CJ.The cost-effectiveness of mammographic screening strategies . Journal of the American Medical Association1995; 274: 881-884 .
40.
Habbema JD , van Oortmarssen GJ , Lubbe JT , van der Maas PJ.The MISCAN simulation program for the evaluation of screening for disease . Computer Methods & Programs in Biomedicine1985; 20: 79-93 .
41.
Eddy DM.Screening for cervical cancer . Annals of Internal Medicine1990; 113: 214-226 .
42.
Fahs MC , Mandelblatt M , Schechter C , Muller C.Cost effectiveness of cervical cancer screening for the elderly . Annals of Internal Medicine1992; 117: 520-527 .
43.
Col N , Eckman M , Karas R , Pauker S , Goldberg R , Ross Eet al.Patient-specific decisions about hormone replacement therapy in postmenopausal women . Journal of the American Medical Association1997; 277: 1140-1146 .
44.
Graham JD , Corso PS , Morris JM , Segui-Gomez M , Weinstein MC.Evaluating the cost-effectiveness of clinical and public health measures . Annual Review of Public Health1998; 19: 125-152 .
45.
Hansen P , Scuffham TA.The cost-effectiveness of compulsory bicycle helmets in New Zealand . Australian Journal of Public Health1995; 19: 45-54 .
46.
Hatziandreu EJ , Sacks JJ , Brown R , Taylor WR , Rosenberg MLet al.The cost-effectiveness of three programs to increase use of bicycle helmets among children . Public Health Report1995; 110: 251-259 .
47.
U. S. Food and Drug Administration (FDA) . Regulations restricting the sale and distribution of cigarette and smokeless tobacco to protect children and adolescents. Final Rule. 21 CFR Parts 801, 803, 804, 807, 820 and 897. RIN 0910-AA48 . Fed Regist1996.
48.
Marcinowski F , Napolitano S.Reducing the risks from radon . Air Waste1998; 43: 955-962 .
49.
Rose G.Strategy of prevention: lessons from cardiovascular disease . British Medical Journal1981; 282: 1874-1951 .
